Lenalidomide (Revlimid™), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma -: First results of a german multicenter phase I/II trial.

被引：0
|
作者：
Knop, Stefan
Gerecke, Christian
Topp, Max S.
Liebisch, Peter
Hess, Georg
Kotkiewitz, Sandra
Einsele, Hermann
Bargou, Ralf
机构：
[1] Univ Hosp, Wurzburg, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Univ Hosp, Ulm, Germany
[4] Univ Hosp, Mainz, Germany
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
408
引用
收藏
页码：125A / 125A
页数：1
相关论文
共 50 条
  • [21] A multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: Preliminary results. Multiple myeloma research consortium (MMRC) trial
    Jakubowiak, A.
    Richardson, P.
    Zimmerman, T.
    Alsina, M.
    Lonial, S.
    Kendall, T.
    Hideshima, T.
    Sportelli, P.
    Birch, R.
    Henderson, I. C.
    Giusti, K.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 154 - 155
  • [22] Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Kennedy, Ryan
    Abbas, Mohammad
    Gill, Navkiranjit
    Dai, Lijun
    Andreas, Carrie
    Gardner, Diane
    Pregja, Silvana Lalo
    Burt, Steve
    Redner, Robert L.
    Volkin, Robert
    Roodman, G. David
    Mapara, Markus Y.
    Viverette, J. Franklin
    Agha, Mounzer
    Waas, John K.
    Shuai, Yongli
    Normolle, Daniel
    Zonder, Jeffrey A.
    BLOOD, 2011, 118 (21) : 142 - 142
  • [23] Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
    Knop, Stefan
    Gerecke, Christian
    Liebisch, Peter
    Topp, Max S.
    Platzbecker, Uwe
    Sezer, Orhan
    Vollmuth, Christina
    Falk, Karina
    Glasmacher, Axel
    Maeder, Uwe
    Einsele, Hermann
    Bargou, Ralf C.
    BLOOD, 2009, 113 (18) : 4137 - 4143
  • [24] Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial.
    Richardson, Paul G.
    Jagannath, S.
    Avigan, D. E.
    Alsina, M.
    Schlossman, R. L.
    Mazumder, A.
    Munshi, N. C.
    Ghobrial, I.
    Doss, D.
    McKenney, M. L.
    Farrell, M. G.
    Warren, D. L.
    Lunde, L. E.
    Gourley, B.
    Vaccaro, S.
    Delaney, C.
    Pountney, S.
    Mitsiades, C. S.
    Hideshima, T.
    Byrne, C.
    Knight, R.
    Birner, A.
    Myers, T.
    Weller, E.
    Anderson, K. C.
    BLOOD, 2006, 108 (11) : 124A - 124A
  • [25] PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
    Bilotti, El
    Vesole, D.
    Richter, J.
    McNeill, A.
    Anand, P.
    Bednarz, U.
    Ivanovski, K.
    McBride, L.
    Raucci, L.
    Batra, V.
    Siegel, D.
    HAEMATOLOGICA, 2013, 98 : 323 - 324
  • [26] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Dhakal, Binod
    D'Souza, Anita
    Hamadani, Mehdi
    Arce-Lara, Carlos
    Schroeder, Katrina
    Chhabra, Saurabh
    Shah, Nirav N.
    Gauger, Katelyn
    Keaton, Taylor
    Pasquini, Marcelo
    Hari, Parameswaran
    BLOOD CANCER JOURNAL, 2019, 9 (8)
  • [27] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Binod Dhakal
    Anita D’Souza
    Mehdi Hamadani
    Carlos Arce-Lara
    Katrina Schroeder
    Saurabh Chhabra
    Nirav N. Shah
    Katelyn Gauger
    Taylor Keaton
    Marcelo Pasquini
    Parameswaran Hari
    Blood Cancer Journal, 9
  • [28] Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse
    Goldschmidt, Hartmut
    Baertsch, Marc-A.
    Schlenzka, Jana
    Becker, Natalia
    Christina, Habermehl
    Hielscher, Thomas
    Raab, Marc S.
    Hillengass, Jens
    Mueller-Tidow, Carsten
    Luntz, Steffen
    Jauch, Anna
    Brossart, Peter
    Goerner, Martin
    Klein, Stefan A.
    Schmidt-Hieber, Martin
    Reimer, Peter
    Graeven, Ullrich
    Fenk, Roland
    Haenel, Mathias
    Martin, Hans
    Lindemann, Hans-Walter
    Scheid, Christoph
    Nogai, Axel
    Salwender, Hans Juergen
    Noppeney, Richard
    Weisel, Katja
    BLOOD, 2018, 132
  • [29] Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Weller, Edie
    Jagannath, Sundar
    Avigan, David E.
    Alsina, Melissa
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    McKenney, Mary
    Delaney, Carol
    Mitsiades, Constantine S.
    Hideshima, Teru
    Dalton, William
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5713 - 5719
  • [30] A multiple myeloma research consortium (MMRC) Multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with Relapsed/Refractory multiple myeloma (MM): Updated results
    Jakubowiak, Andrzej
    Zimmerman, Todd
    Alsina, Melissa
    Richardson, Paul
    Kaufman, Jonathan
    Kendall, T.
    Brozo, C.
    McAllister, A.
    Leister, C.
    Hideshima, T.
    Sportelli, P.
    Gardner, L.
    Birch, R.
    Henderson, I. C.
    Giusti, K.
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 354A - 354A
12345